Autolus Therapeutics plc (AUTL)’s Financial Results Comparing With SIGA Technologies Inc. (NASDAQ:SIGA)

Both Autolus Therapeutics plc (NASDAQ:AUTL) and SIGA Technologies Inc. (NASDAQ:SIGA) are Biotechnology companies, competing one another. We will compare their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Autolus Therapeutics plc 1.08M 642.65 53.28M -1.40 0.00
SIGA Technologies Inc. 485.76M 0.91 435.02M 5.13 1.10

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Autolus Therapeutics plc and SIGA Technologies Inc.

Net Margins Return on Equity Return on Assets
Autolus Therapeutics plc -4,933.33% 0% 0%
SIGA Technologies Inc. 89.55% 0% 0%

Insider and Institutional Ownership

Roughly 45.07% of Autolus Therapeutics plc shares are held by institutional investors while 30.2% of SIGA Technologies Inc. are owned by institutional investors. Insiders held 3.52% of Autolus Therapeutics plc shares. Comparatively, SIGA Technologies Inc. has 2.6% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Autolus Therapeutics plc 2.8% -14.64% -18.32% -50.22% 0% -27.22%
SIGA Technologies Inc. 2.91% 6% -14% 12.1% -13.87% -28.48%

For the past year Autolus Therapeutics plc was less bearish than SIGA Technologies Inc.

Summary

SIGA Technologies Inc. beats on 7 of the 9 factors Autolus Therapeutics plc.

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

SIGA Technologies, Inc. engages in the development and commercialization of solutions for unmet medical needs and biothreats in the United States. Its lead product is TPOXX, an orally administered antiviral drug for treating orthopoxvirus infections. SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.